Published in Ann Intern Med on November 01, 1991
Chemotherapy combined with chest irradiation for locally advanced non-small cell lung cancer. Ann Intern Med (1991) 1.37
Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. Br J Cancer (1995) 1.29
NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. Br J Cancer (2006) 0.98
Factors predicting radiation pneumonitis in locally advanced non-small cell lung cancer. Radiat Oncol J (2011) 0.95
Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer (1999) 0.87
CT-guided implantation of radioactive 125I seed in advanced non-small-cell lung cancer after failure of first-line chemotherapy. J Cancer Res Clin Oncol (2014) 0.84
The role of taxanes in the management of gastroesphageal cancer. J Gastrointest Oncol (2011) 0.82
A Pilot Study (SWOG S0429) of Weekly Cetuximab and Chest Radiotherapy for Poor-Risk Stage III Non-Small Cell Lung Cancer. Front Oncol (2013) 0.81
Continuous carboplatin infusion during 6 weeks' radiotherapy in locally inoperable non-small-cell lung cancer: a phase I and pharmacokinetic study. Br J Cancer (1995) 0.80
Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Br J Cancer (2002) 0.80
Concurrent conventionally factionated radiotherapy and weekly docetaxel in the treatment of stage IIIb non-small-cell lung carcinoma. Br J Cancer (1999) 0.79
Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2007) 0.77
Preclinical and pilot clinical studies of docetaxel chemoradiation for Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys (2010) 0.75
A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06
Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med (1991) 7.21
A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology (2001) 5.16
Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet (2000) 4.43
Primary mediastinal tumors: part II. Tumors of the middle and posterior mediastinum. Chest (1997) 4.10
Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol (1989) 4.03
Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. JAMA (1993) 3.91
Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med (1995) 3.83
Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol (1989) 3.44
Superior pulmonary sulcus tumors and Pancoast's syndrome. N Engl J Med (1997) 3.29
Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med (1994) 3.29
Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA (2000) 3.15
Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol (1997) 3.04
Primary mediastinal tumors. Part 1: tumors of the anterior mediastinum. Chest (1997) 2.91
Megestrol acetate for the prevention of hot flashes. N Engl J Med (1994) 2.72
A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine. N Engl J Med (1997) 2.66
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol (1998) 2.51
The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol (2001) 2.41
Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med (1997) 2.25
Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics (1995) 2.19
Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology (2001) 2.09
Systemic candidiasis in cancer patients. Am J Med (1984) 2.05
Secular trends in hip fracture incidence and recurrence. Osteoporos Int (2008) 2.04
Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol (1991) 1.93
Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol (1994) 1.93
Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst (1990) 1.92
Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis. Gastroenterology (1996) 1.87
A new immunodeficiency disorder in humans involving NK cells. Nature (1980) 1.78
Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia (2008) 1.77
Weight change in women treated with adjuvant therapy or observed following mastectomy for node-positive breast cancer. J Clin Oncol (1990) 1.74
Long-term trends in hip fracture prevalence: the influence of hip fracture incidence and survival. Osteoporos Int (1998) 1.69
Prospective evaluation of prognostic variables from patient-completed questionnaires. North Central Cancer Treatment Group. J Clin Oncol (1994) 1.67
A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. J Natl Cancer Inst (1996) 1.58
Designs for group sequential phase II clinical trials. Biometrics (1987) 1.57
Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology (2000) 1.55
Natural history of hereditary cancer of the breast and colon. Cancer (1982) 1.53
Phase II evaluation of menogaril in patients with advanced hypernephroma. Invest New Drugs (1991) 1.53
Dietary folate intake, alcohol, and risk of breast cancer in a prospective study of postmenopausal women. Epidemiology (2001) 1.53
Approach to the solitary pulmonary nodule. Mayo Clin Proc (1993) 1.51
Primary central nervous system non-Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys (1995) 1.51
Olsalazine is contraindicated during pelvic radiation therapy: results of a double-blind, randomized clinical trial. Int J Radiat Oncol Biol Phys (1996) 1.50
Ten-year outcomes for pathologic node-positive patients treated in RTOG 75-06. Int J Radiat Oncol Biol Phys (1998) 1.49
Evaluation of consultation-based rehabilitation for hospitalized cancer patients with functional impairment. Mayo Clin Proc (1999) 1.48
Radiation therapy for glottic cancer using 6-MV photons. Cancer (1996) 1.48
An integrated approach to evaluation of the solitary pulmonary nodule. Mayo Clin Proc (1990) 1.47
Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology (1998) 1.46
A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc (2000) 1.45
Iron overload in cirrhosis-HFE genotypes and outcome after liver transplantation. Hepatology (2000) 1.45
Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol (2001) 1.45
Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia (2012) 1.44
Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol (2001) 1.42
Normalization of two-channel microarray experiments: a semiparametric approach. Bioinformatics (2004) 1.42
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study. J Clin Oncol (1998) 1.42
Chédiak-Higashi gene in humans. II. The selectivity of the defect in natural-killer and antibody-dependent cell-mediated cytotoxicity function. J Exp Med (1980) 1.41
Long-term follow-up of radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2004) 1.40
Impact of radiation dose and tumor size on large cell lymphoma patients in complete response after integrated CHOP-Bleo-radiation treatment protocol. Int J Radiat Oncol Biol Phys (1995) 1.40
Daclizumab induction therapy in liver transplant recipients with renal insufficiency. Aliment Pharmacol Ther (2010) 1.40
Clinical significance of nuclear DNA ploidy pattern in nonseminomatous germ cell testicular tumors. Urology (1994) 1.39
Radiation therapy for squamous cell carcinoma of the tonsil. Mayo Clin Proc (1994) 1.39
Linear accelerator sypervoltage radiation therapy: testicular tumors. Radiology (1968) 1.38
Bolus versus infusion regimens of etoposide and cisplatin in treatment of non-small cell lung cancer: a study of the North Central Cancer Treatment group. J Natl Cancer Inst (1990) 1.37
Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomized trial. Arch Surg (1990) 1.34
The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: characteristics of patients enrolled and not enrolled. COMS Report No. 17. Arch Ophthalmol (2001) 1.34
Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. J Clin Oncol (1991) 1.33
The correlation of emphysema or airway obstruction with the risk of lung cancer: a matched case-controlled study. Eur Respir J (2002) 1.33
Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol (1994) 1.33
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol (1997) 1.31
Lumbar lordosis and pelvic inclination in adults with chronic low back pain. Phys Ther (2000) 1.30
Prognosis of histological cirrhosis in type 1 autoimmune hepatitis. Gastroenterology (1996) 1.29
Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res (1996) 1.29
A controlled evaluation of recent approaches to biochemical modulation or enhancement of 5-fluorouracil therapy in colorectal carcinoma. J Clin Oncol (1985) 1.29
Differential diagnosis between radiation and tumor plexopathy of the pelvis. Neurology (1985) 1.28
Regression analysis for comparing protein samples with 16O/18O stable-isotope labeled mass spectrometry. Bioinformatics (2006) 1.27
Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. J Clin Oncol (1998) 1.26
The value of bronchoscopy in the diagnosis of mycobacterial disease. A five-year experience. Chest (1981) 1.25
Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol (1993) 1.25
Phase II evaluation of recombinant interferon alpha and BCNU in recurrent glioma. J Neurosurg (1995) 1.25
Long-term survival (10 years or more) in 30 patients with primary amyloidosis. Blood (1999) 1.24
Typical and atypical pulmonary carcinoids : outcome in patients presenting with regional lymph node involvement. Chest (2001) 1.21
Retrospective cohort study of 148 patients with polyclonal gammopathy. Mayo Clin Proc (2001) 1.20
Cost-effectiveness of 6 and 12 months of interferon-alpha therapy for chronic hepatitis C. Ann Intern Med (1997) 1.20
Increased risk of chronic liver failure in adults with heterozygous alpha1-antitrypsin deficiency. Hepatology (1998) 1.19
Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small-cell lung cancer. J Clin Oncol (1994) 1.18